Clinical Trial Update: A Phase I/II Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of the EMB-07 Combination Therapy in Patients With Aggressive B-Cell Non-Hodgkin Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

Phase I/II clinical trial evaluating EMB-07 in combination therapy for aggressive B-cell non-Hodgkin lymphoma; currently not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aggressive B-cell Non-hodgkin Lymphoma

Drugs mentioned

• EMB-07 (EMB-07)

Snippet

Sponsor: Shanghai EpimAb Biotherapeutics Co., Ltd. | Conditions: Combination Therapy, Aggressive B-Cell Non-Hodgkin Lymphoma | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING